No idea. The positive remarks only referenced the Striate deal and the possibility that the company could be self-sustaining with respect to funding from here on, but could have generated a bit of further investigation by motivated budding investors. I suspect a couple of years ago results like this would have put a rocket under the share price.
Now, not so much.
Ann: Successful OrthoATI clinical trial, page-36
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.005(1.25%) |
Mkt cap ! $82.68M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 39.0¢ | $65.71K | 166.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1052 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 354895 | 8 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |